Abstract

Uterine leiomyomas (uterine fibroids) are sex-steroid dependent benign tumors. Limited knowledge is available regarding the role of estrogen and their receptors in the regulation of fibroids in premenopausalwomen ,and in their shrinkage after treatment with a gonadotropin-releasing hormone analogue (GnRHa). The expression of the two subtypes of the estrogen receptor (ER) ,ERα and ERβ,was studied in leiomyoma and homologous myometrium from women in the proliferative phase of the menstrual cycle and from women treated with GnRHa. The mRNA levels of ERα and ERβwere monitored by solution hybridization and in situ hybridization ,and receptor proteins were detected and localized by immuno-histochemistry. Both ERα and ERβ were present inthe leiomyomas and homologous myometrium. The ERα mRNA level in the leiomyomas was higher than in the surrounding myometrium. The ERβ mRNA level was lower than that of ERαin both groups. ERβ immunoreactivity was lower in leiomyomas when compared with the myometrium after GnRHa treatment ,while ERα was higher in the leiomyomas. The present resultsimply that the increased ratio of ERα/ERβ observed in the fibroids after GnRHa treatment could reflect or be the cause of the shrinkage of the leiomyoma ,which is the clinical outcomeof this treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.